This review article discusses the therapeutic potential of gene editing, focusing on mRNA-based delivery systems. It highlights the advancements in gene editing technologies like CRISPR-Cas systems and base editors, and examines their applications in treating genetic disorders.


Key Points

1. Gene Editing Technologies:

  • CRISPR-Cas Systems: Recognize target DNA sequences via RNA-DNA hybridization, enabling precise cuts in the DNA.
  • Base Editors: Allow single-nucleotide changes without creating double-stranded breaks, reducing the risk of off-target effects.


2. mRNA Delivery Advantages:

  • Transient expression provides controlled, time-limited therapeutic effects.
  • Avoids genomic integration, preserving the host genome’s integrity.
  • Reduced immunogenicity compared to viral vectors.


3. Applications:

  • Ex Vivo Gene Editing: Genetic modification of cells outside the body before reintroduction.
  • In Vivo Gene Editing: Direct editing of genes within the body.


4. Next-Generation CRISPR Systems:

  • Designed to minimize off-target effects and enable precise gene modifications.
  • Include base editors capable of making specific nucleotide changes without DNA cleavage.


5. Therapeutic Potential:

  • mRNA-based gene editing shows promise for treating a variety of genetic disorders.
  • Focus on improving delivery methods to enhance therapeutic efficacy and safety.


The combination of CRISPR technology and mRNA delivery represents a significant advancement in gene therapy. This approach offers a safer and more precise method for gene editing, with potential applications in treating a wide range of genetic diseases. Ongoing research aims to further refine these technologies and explore new therapeutic possibilities.

Check out our Fast mRNA Service for Gene Editing
Source: Juliana Popovitz, Rohit Sharma, Reyhane Hoshyar, Beob Soo Kim, Niren Murthy, Kunwoo Lee,
Gene editing therapeutics based on mRNA delivery, Advanced Drug Delivery Reviews, Volume 200, 2023, 115026, ISSN 0169-409X, https://doi.org/10.1016/j.addr.2023.115026.
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

More Articles

Lou Gehrig’s Disease: Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS), commonly known as "Lou Gehrig's disease," is a rare neurodegenerative condition and one of the world's five major incurable diseases. It is characterized by the gradual loss of neurons in the brain, brainstem, and spinal cord that...

read more

Related Services


AAV Packaging Services



AAV Packaging Service (NHP)



AAV Packaging Service (HT)